Financial Architects (New Jersey)’s Ligand Pharmaceuticals LGND Stock Holding History

Financial Architects (New Jersey)’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,206	Closed	-$272K	–	1545
2017 Q3	$272K	Buy	+3,206	New	+$254K	0.05%	260
2016 Q1	–	Sell	-6,412	Closed	-$434K	–	1166
2015 Q4	$434K	Hold	6,412	–	–	0.17%	122
2015 Q3	$343K	Hold	6,412	–	–	0.14%	138
2015 Q2	$404K	Hold	6,412	–	–	0.15%	121
2015 Q1	$308K	Hold	6,412	–	–	0.12%	135
2014 Q4	$213K	Buy	+6,412	New	+$209K	0.09%	162

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Financial Architects (New Jersey)'s LGND Position: Q4 2017 in Review

Financial Architects (New Jersey) sold out of Ligand Pharmaceuticals (LGND) in Q4 2017, closing a stake of 3,206 shares — an estimated $272K sold.

Financial Architects (New Jersey) first reported a position in LGND in Q4 2014 and held it in 6 quarters. The position peaked at $434K in Q4 2015. 298 funds tracked by Wall St. Rank hold LGND as of Q4 2017.

Financial Architects (New Jersey) reported no remaining Ligand Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Financial Architects (New Jersey) sold 3,206 Ligand Pharmaceuticals shares in Q4 2017, an estimated $272K.
Financial Architects (New Jersey) first reported a position in Ligand Pharmaceuticals in Q4 2014 and held it in 6 quarters.
Financial Architects (New Jersey)'s Ligand Pharmaceuticals position peaked at $434K in Q4 2015.
298 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2017.

Based on Financial Architects (New Jersey)'s 13F filing for Q4 2017, filed 12 Feb 2018.